Regarding the data for FY2021 marked with ★, we have received independent assurance in our SUSTAINABILITY DATA 2022 (PDF version) so as to bolster the reliability of the information. For details, please see the “Independent Practitioner's Assurance.”Governance Data
Item | Scope | Unit | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | |
---|---|---|---|---|---|---|---|---|
Board structure | Directors (Total) | Non-consolidated | Persons | 7 | 8 | 8 | 8 | 8 |
Independent outside directors | Non-consolidated | Persons | 2 | 3 | 3 | 3 | 3 | |
Female directors | Non-consolidated | Persons | 0 | 0 | 0 | 1 | 1 | |
Board of Auditors structure | Auditors (Total) | Non-consolidated | Persons | 4 | 4 | 4 | 4 | 4 |
Independent outside auditors | Non-consolidated | Persons | 2 | 2 | 2 | 2 | 2 | |
Female auditors | Non-consolidated | Persons | 1 | 1 | 1 | 1 | 1 | |
Director Remuneration | Total | Non-consolidated | Million yen | 336 | 360 | 368 | 384 | 428 |
President, Representative Director, and Chief Executive Officer | Non-consolidated | Million yen | - | 114 | 116 | 126 | 125 | |
Auditor Remuneration | Total | Non-consolidated | Million yen | 76 | 77 | 78 | 83 | 85 |
Number of Board of Directors meetings | Non-consolidated | Times | 13 | 13 | 13 | 13 | 15 | |
Number of Board of Auditors meetings | Non-consolidated | Times | 13 | 14 | 14 | 19 | 16 | |
Board attendance rate(directors) | Non-consolidated | % | 100 | 100 | 100 | 98.6 | 100 | |
Board attendance rate(auditors) | Non-consolidated | % | - | 100 | 92.3*1 | 100 | 100 |
Item | Scope | Unit | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | |
---|---|---|---|---|---|---|---|---|
Compliance training attendance rate | Non-consolidated | % | - | 100 | 100 | 100 | 100 | |
Number of reports | Discrimination and harassment related | Non-consolidated | Incidents | - | - | 22 | 15 | 29 |
Personnel and labor management related | Non-consolidated | Incidents | - | - | 2 | 1 | 2 | |
Others | Non-consolidated | Incidents | - | - | 44 | 6 | 29 | |
Total | Non-consolidated | Incidents | - | 44 | 68 | 22 | 60 | |
Number of compliance violations(Disciplinary action cases) | Discrimination and harassment related | Non-consolidated | Incidents | - | - | 3 | 1 | 0 |
Personnel and labor management related | Non-consolidated | Incidents | - | - | 0 | 0 | 1 | |
Bribery cases | Non-consolidated | Incidents | 0 | 0 | 0 | 1 | 0 | |
Others | Non-consolidated | Incidents | - | - | 6 | 0 | 10 | |
Total | Non-consolidated | Incidents | - | 5 | 9 | 2 | 11 | |
Costs for legal violations | Non-consolidated | Million yen | - | - | - | 0 | 0 | |
Number of facilitation payments | Non-consolidated | Incidents | 0 | 0 | 0 | 0 | 0 |
Item | Scope | Unit | FY2017 | FY2018 | FY2019 | FY2020 | ★FY2021 | ||
---|---|---|---|---|---|---|---|---|---|
GHG emissions (Market-basis) | Production and research sites | kt-CO2 | 27.2 | 26.1 | 25.2 | 24.1 | 21.8 | ||
Headquarters and other Sites in Japan (including tenant locations) | kt-CO2 | 2.6 | 2.4 | 2.1 | 2.0 | 1.7 | |||
Total | kt-CO2 | 29.8 | 28.5 | 27.3 | 26.1 | 23.6 | |||
GHG emissions scope breakdown (Market-basis) | Scope 1 (Breakdown by GHG type) | Energy-derived | All operation sites | kt-CO2 | 8.5 | 9.0 | 9.7 | 10.0 | 9.8 |
Non-energy-derived (HFCs, HCFCs) |
0.2 | 0.5 | 0.4 | 0.1 | 0.03 | ||||
Total | 8.7 | 9.5 | 10.1 | 10.1 | 9.8 | ||||
Scope 2 | All operation sites | kt-CO2 | 21.1 | 19.1 | 17.1 | 15.9 | 13.7 | ||
Amount of CO2 offset due to voluntary credit(Carbon-neutral city gas purchased) | Joto Pharmaceutical Product Development Center, Tsukuba Research Institute | kt-CO2 | - | - | - | - | 0.6 | ||
GHG emissions after offset | All operation sites | kt-CO2 | - | - | - | - | 23.0 |
Category | Calculation method | Notes | Scope | Unit | FY2017 | FY2018 | FY2019 | FY2020 | ★FY2021 | |
---|---|---|---|---|---|---|---|---|---|---|
Cat1 | Purchased goods and services | GHG emissions (scope 1,2) volume of our major suppliers of raw materials and materials (accounting for 80% or more of our raw materials or materials purchase costs) multiplied by the ratio of the sales to ONO out of the total sales of the supplier. Ratios for other business suppliers are assumed to follow the same trend as for major suppliers, and are calculated using the ratio of GHG emissions to the transaction amount at major suppliers. | ·This category is closely associated with our business activities since active pharmaceutical ingredients for manufacturing of drugs, intermediate products and research reagents are included. ·Covers production and research sites ·Figures for FY2021 are not calculated because our major suppliers had not published their CSR reports at the time of calculation. |
All operation sites | kt-CO2 | 8.5 | 8.1 | 11.5 | 12.7 | - |
Cat2 | Capital goods | Amount of capital goods treated as fixed assets (reinforcement of facilities/maintenance investment) excluding land, multiplied by factor | Calculated based on capital goods treated as fixed assets. The fixed assets used in this calculation are essential for business activities. | kt-CO2 | 52.6 | 60.4 | 26.9 | 25.8 | 26.4 | |
Cat3 | Fuel- and energy-related activities not included in scope 1 or scope 2 | Amount of non-renewable electricity purchased, multiplied by emission factor | - | kt-CO2 | 1.5 | 1.5 | 2.8 | 2.7 | 2.4 | |
Cat4 | Upstream transportation and distribution | Transport data on deliveries from our production sites and distribution centers to destinations, multiplied by emission factor | - | kt-CO2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
Cat5 | Waste generated in operations | Weight of each type of industrial waste generated, multiplied by emission factor | - | kt-CO2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | |
Cat6 | Business travel | Business travel costs, multiplied by emission factor | Covers travels by airplane or Shinkansen bullet train | kt-CO2 | 2.5 | 2.3 | 4.0 | 0.4 | 0.5 | |
Cat7 | Employee commuting | Commuting costs, multiplied by emission factor | The commuting costs includes the amount for commuting by car from 2021 | kt-CO2 | 0.4 | 0.4 | 0.5 | 0.4 | 0.7 | |
Cat8 | Upstream leased assets | Fuel consumption used in leased vehicles, multiplied by emission factor | - | kt-CO2 | 3.5 | 3.3 | 2.9 | 2.0 | 2.1 | |
Cat9 | Downstream transportation and distribution | GHG emissions stated in CSR reports on our major pharmaceutical wholesalers, multiplied by percentage of our net sales included in all net sales of major pharmaceutical wholesalers | ·Transportation and distribution are important business activities to control distribution of and to ensure stable supply of drugs. · Figures for FY2021 are not calculated because our major pharmaceutical wholesalers had not published their CSR reports at the time of calculation. |
kt-CO2 | 5.3 | 5.3 | 4.9 | 5.0 | - | |
Cat10 | Processing of sold products | - | We make only finished products | kt-CO2 | Not relevant | Not relevant | Not relevant | Not relevant | Not relevant | |
Cat11 | Use of sold products | - | No energy is consumed during the use of ONO products | Not relevant | Not relevant | Not relevant | Not relevant | Not relevant | ||
Cat12 | End-of-life treatment of sold products | Weight of each type of our product container or packaging disposed of as waste, multiplied by emission factor | - | kt-CO2 | 0.1 | 0.2 | 0.2 | 0.2 | 0.1 | |
Cat13 | Downstream leased assets | Floor space of asset (building) owned and rented out categorized by use, multiplied by emission factor | - | kt-CO2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | |
Cat14 | Franchises | - | ONO does not operate franchises | kt-CO2 | Not relevant | Not relevant | Not relevant | Not relevant | Not relevant | |
Cat15 | Investments | - | There is no investment involving large amounts of greenhouse gas emissions. | kt-CO2 | Not relevant | Not relevant | Not relevant | Not relevant | Not relevant | |
Total | kt-CO2 | 75.1 | 82.2 | 54.4 | 49.8 | - |
Item | Scope | Unit | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | ||
---|---|---|---|---|---|---|---|---|---|
Energy consumption | Production and research sites | MWh | 83,906.2 | 88,423.4 | 96,369.2 | 98,025.2 | ★94,433.7 | ||
Headquarters and other Japan offices/sites (including tenant locations) | MWh | 5,256.9 | 5,340.4 | 5,236.4 | 5,179.1 | ★5,004.3 | |||
Total | MWh | 89,163.1 | 93,763.8 | 101,605.6 | 103,204.3 | ★99,438.0 | |||
Share of renewable energy in total electricity consumption | Electricity consumption | Private power generation (renewable) (solar power generation) | All operation sites | MWh | 55.3 | 65.0 | 63.0 | 63.3 | 61.9 |
Purchased electricity (renewable) (Non-fossil fuel) | MWh | - | - | 1,278.0 | 1,954.7 | 2,040.0 | |||
Private power generation (non-renewable) | MWh | 7,927.0 | 8,856.2 | 8,185.3 | 8,566.3 | 8,283.7 | |||
Purchased electricity (non-renewable) | MWh | 41,820.1 | 43,734.4 | 46,351.7 | 45,232.2 | 42,833.5 | |||
Total (total electricity consumption) |
MWh | 49,802.4 | 52,655.5 | 55,878.0 | 55,816.5 | 53,219.2 | |||
Amount of credits purchased | Solar power generation | MWh | - | - | 2,427.0 | 4,946.6 | 3,937.9 | ||
Biomass power generation | MWh | - | 2,900.0 | 2,460.9 | 386.2 | 3,000.0 | |||
Renewable energy usage*5 | MWh | 55.3 | 2,965.0 | 6,228.9 | 7,350.7 | ★9,039.9 | |||
Renewable energy usage rate (renewable energy usage / total electricity consumption) | % | 0.1 | 5.6 | 11.1 | 13.2 | ★17.0 |
Site name | River in the area | Wastewater drainage destination | FY2017 | FY2018 | FY2019 | FY2020 | ★FY2021 | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Water intake volume | Wastewater volume | Water intake volume | Wastewater volume | Water intake volume | Wastewater volume | Water intake volume | Wastewater volume | Water intake volume | Wastewater volume | |||
Fujiyama Plant | Fuji River | River | 205.6 | 148.6 | 240.2 | 178.4 | 185.0 | 145.1 | 157.8 | 125.0 | 138.7 | 110.2 |
Joto Pharmaceutical Product Development Center | Yodo River | Sewer | 5.5 | 5.5 | 6.0 | 6.0 | 5.1 | 5.1 | 4.6 | 4.6 | 3.9 | 3.9 |
Yamaguchi Plant | Fushino River | River | - | - | 8.2 | 8.2 | 18.1 | 18.1 | 18.6 | 17.7 | 21.6 | 20.0 |
Minase Research Institute | Yodo River | Sewer | 51.3 | 51.3 | 41.2 | 41.2 | 39.1 | 39.1 | 33.7 | 33.7 | 31.5 | 31.5 |
Fukui Research Institute | Kuzuryu River | Sewer | 38.7 | 5.2 | 31.3 | 5.0 | 27.3 | 5.7 | 13.7 | 2.6 | 6.6 | 1.9 |
Tsukuba Research Institute | Lake Kasumigaura | Sewer | 8.1 | 8.1 | 6.0 | 6.0 | 7.1 | 7.1 | 7.2 | 7.2 | 7.0 | 7.0 |
Head Office and other sites in Japan (including tenant locations) | Rivers/lake in the areas where major business sites are located*6 | Sewer | 15.9 | 15.9 | 15.1 | 15.1 | 15.0 | 15.0 | 10.0 | 10.0 | 10.0 | 10.0 |
Total | 325.1 | 234.6 | 348.0 | 259.9 | 296.7 | 235.2 | 245.6 | 200.8 | 219.4 | 184.5 |
Item | Scope | Unit | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
---|---|---|---|---|---|---|---|
Percentage of reused water | Production and research sites | % | 5.9 | 4.8 | 5.5 | 2.0 | 1.6 |
Item | Scope | Unit | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | |
---|---|---|---|---|---|---|---|---|
Industrial waste | Waste generated | Production and research sites, etc. | t | 719.1 | 446.4 | 430.8 | 502.7 | ★479.1 |
Special management industrial waste (hazardous waste)*7 | Production and research sites, etc. | t | 137.0 | 145.6 | 161.9 | 171.2 | ★170.3 | |
final landfill disposal | Production and research sites, etc. | t | 7.4 | 0.4 | 0.2 | 1.1 | ★0.2 | |
final landfill disposal rate | Production and research sites, etc. | % | 1.0 | 0.1 | 0.1 | 0.2 | ★0.04 | |
final landfill disposal (Non-industrial waste is included) | Production and research sites | t | 18.0 | 9.4 | 6.7 | 5.9 | 5.3 | |
Container and packaging usage | Plastic | Production | t | 164.7 | 171.7 | 162.8 | 161.5 | 147.0 |
Paper | Production | t | 192.0 | 202.7 | 200.9 | 198.1 | 175.6 | |
Glass (colorless) | Production | t | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
Glass (brown) | Production | t | 0.3 | 0.3 | 0.3 | 0.2 | 0.2 | |
Obligatory recycling amount | Plastic | Production | t | 34.7 | 35.5 | 31.2 | 35.1 | 36.6 |
Paper | Production | t | 1.6 | 1.6 | 1.5 | 1.4 | 1.3 | |
Glass (colorless) | Production | t | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
Glass (brown) | Production | t | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
Commissioning fee paid for recycling | Production | 1,000 yen | 1,723.0 | 1,650.0 | 1,546.0 | 1,814.0 | 1,958.0 |
Item | Scope | Unit | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | |
---|---|---|---|---|---|---|---|---|
Emissions into the air | SOx | Production and research sites | t | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
NOx | Production and research sites | t | 7.8 | 8.4 | 8.1 | 8.1 | 8.3 | |
Particulate matter | Production and research sites | t | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | |
PRTR substance | Production and research sites | t | 0.2 | 0.2 | 0.1 | 0.4 | 0.3 | |
Emissions into water | Wastewater | Production and research sites | 1,000m3 | 218.7 | 244.8 | 220.2 | 190.8 | ★174.5 |
BOD | Production and research sites | t | 2.2 | 1.3 | 1.3 | 1.2 | 1.3 | |
PRTR substance | Production and research sites | t | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Item | Scope | Unit | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | |
---|---|---|---|---|---|---|---|---|
Amount handled by the notified facilities | Acetonitrile | Production and research sites | t | 9.0 | 7.2 | 8.5 | 10.4 | 9.3 |
Normal-hexane | Production and research sites | t | 3.0 | 2.8 | 3.0 | 2.6 | 2.3 | |
Total | Production and research sites | t | 12.0 | 10.0 | 11.5 | 13.0 | 11.6 | |
Dioxins | Production and research sites | mg-TEQ | - | - | - | - | - | |
Notified release (into the air) | Acetonitrile | Production and research sites | t | 0.4 | 0.2 | 0.1 | 0.3 | 0.3 |
Normal-hexane | Production and research sites | t | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
Total | Production and research sites | t | 0.4 | 0.2 | 0.1 | 0.3 | 0.3 | |
Dioxins | Production and research sites | mg-TEQ | - | - | - | - | - | |
Notified release (into public waters) | Acetonitrile | Production and research sites | t | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Normal-hexane | Production and research sites | t | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
Total | Production and research sites | t | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
Dioxins | Production and research sites | mg-TEQ | - | - | - | - | - | |
Notified transfer (contained in waste) | Acetonitrile | Production and research sites | t | 8.8 | 6.9 | 8.4 | 10.1 | 8.9 |
Normal-hexane | Production and research sites | t | 3.0 | 2.8 | 3.0 | 2.6 | 2.3 | |
Total | Production and research sites | t | 11.8 | 9.8 | 11.3 | 12.7 | 11.3 | |
Dioxins | Production and research sites | mg-TEQ | 0.0 | - | - | - | - | |
Notified transfer (Into public sewage) | Acetonitrile | Production and research sites | t | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Normal-hexane | Production and research sites | t | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
Total | Production and research sites | t | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
Dioxins | Production and research sites | mg-TEQ | - | - | - | - | - | |
Notified release and transfer (total) | Acetonitrile | Production and research sites | t | 9.0 | 7.2 | 8.5 | 10.4 | 9.3 |
Normal-hexane | Production and research sites | t | 3.0 | 2.8 | 3.0 | 2.6 | 2.3 | |
Total | Production and research sites | t | 12.0 | 10.0 | 11.5 | 13.0 | 11.6 | |
Dioxins | Production and research sites | mg-TEQ | - | - | - | - | - |
Item | Scope | Unit | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | |
---|---|---|---|---|---|---|---|---|
Joto Pharmaceutical Product Development Center | In use or stored | Production and research sites | Stand | 552 | 552 | 0 | 0 | 0 |
Minase Research Institute | In use or stored | Production and research sites | Stand | 0 | 0 | 0 | 0 | 2 |
Item | Scope | Unit | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
---|---|---|---|---|---|---|---|
Status of acquisition of ISO 14001 certification for sites | Production | site | 100% | 100% | 100% | 100% | 100% |
Item | Scope | Unit | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
---|---|---|---|---|---|---|---|
Number of breaches of legal obligation/regulatory violations | All operation sites | Cases | 0 | 0 | 0 | 0 | 0 |
Amount of breach-/violation-related fines | All operation sites | Million yen | 0 | 0 | 0 | 0 | 0 |
Environmental liabilities as of fiscal year-end | All operation sites | Million yen | 0 | 0 | 0 | 0 | 0 |
Item | Scope | Unit | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
---|---|---|---|---|---|---|---|
Osamu Hayaishi Memorial Award | - | Persons | 1 | 1 | 1 | 1 | 1 |
Recipients of theresearch grant | - | Persons | 12 | 12 | 12 | 12 | 12 |
Recipients of theresearch scholarship grant(40 years old and below) | - | Persons | 16 | 16 | 16 | 16 | 16 |
Recipients of the Osamu Hayaishi Memorial Scholarship for Study Abroad | - | Persons | 8 | 8 | 8 | 8 | 8 |